Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , ... 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity testing of compounds in ...
(Date:10/13/2015)... 2015 ARRY ), Avanex Life ... JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ... Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ... --> Cooperative research and development efforts with ... lead to advancements in the treatment of severe wounds. ...
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove Biosciences, a ... their partnership with the Keck Medicine of the University of Southern California ... T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Association ...
Breaking Biology Technology:
(Date:10/6/2015)... Calif. , Oct. 6, 2015  Maverix ... today announced enhancements to its software portfolio with ... analysis kit for differential expression in eukaryotes. The ... which is a cloud-based genomic analysis solution that ... scientific discovery from next-generation sequencing efforts. ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
Breaking Biology News(10 mins):